Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.

Yeh, C.H., Tseng, R., Zhang, Z., Cortes, J., O'Brien, S., Giles, F., Hannah, A., Estrov, Z., Keating, M., Kantarjian, H., Albitar, M.
Journal   Leuk Res.
Analytes Measured   HSP70
Matrix Tested   Plasma
Year   2009
Volume   33
Page Numbers   212-7
Application   Phosphoproteins
We evaluated the association of circulating levels of heat shock protein 70 (Hsp70) in plasma with clinical behavior and progression in 139 chronic myeloid leukemia (CML) patients. Circulating Hsp70 levels did not differ significantly between CML patients in the chronic phase (n=93; median 33.24 ng/mL, range 3.89-128.2 ng/mL) and those in the accelerated/blast phase (n=46; median 26.57 ng/mL, range 4.5-114.7 ng/mL). However, overall CML patients had significantly higher levels of Hsp70 than healthy subjects (n=95, median 4.17 ng/mL, range 1.75-24.7 ng/mL) (P<0.001). In chronic phase CML patients, Hsp70 levels above the median were associated with a higher rate of progression to the accelerated/blast phase and a tendency toward shorter survival. Plasma Hsp70 thus could be a potential marker for predicting disease progression in patients with chronic phase CML.

View Publications

Related Products

R-PLEX Human HSP70 Antibody Set
HSP70 | Human
Browse Our Products

By Analytes
By Applications
Customer Service/Orders

Scientific/Technical Support

Instrument Support

Company Headquarters